Zura Bio Limited (NASDAQ:ZURA – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.75.
ZURA has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, July 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Wall Street Zen lowered shares of Zura Bio from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. Finally, William Blair initiated coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company.
Check Out Our Latest Analysis on Zura Bio
Zura Bio Price Performance
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, analysts expect that Zura Bio will post -0.76 EPS for the current year.
Institutional Trading of Zura Bio
A number of institutional investors have recently bought and sold shares of ZURA. Allworth Financial LP acquired a new position in shares of Zura Bio during the 4th quarter worth about $30,000. Scientech Research LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $45,000. Dimensional Fund Advisors LP acquired a new stake in shares of Zura Bio during the 4th quarter worth about $123,000. Squarepoint Ops LLC purchased a new stake in Zura Bio during the third quarter worth approximately $109,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Zura Bio during the third quarter worth approximately $138,000. 61.14% of the stock is owned by hedge funds and other institutional investors.
About Zura Bio
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
Featured Stories
- Five stocks we like better than Zura Bio
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
